Recent Updates
Recently added Catalysts
EYPT Positive Sentiment

EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference

Wednesday, May 31, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: EyePoint Pharmaceuticals, Inc. will present an overview at the Jefferies Healthcare Conference on June 7, 2023. George Elston, the Chief Financial Officer, will lead the presentation that can be accessed via a live webcast and an archived replay afterward. The company focuses on developing therapies for serious eye disorders, with its Durasert technology being central to its product offerings.
Price reaction · baseline $5.84 (2023-05-30 close) · hit after-hours · 1 other EYPT headline(s) in the window, move may be shared
day 0 close · peak
+3.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • George Elston will present at a prominent conference, enhancing visibility.
  • Company is committed to improving patients' lives through innovative therapeutics.
  • The Durasert technology has a good safety record across approved products.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+28%
120-day peak, hindsight
Typical move
53.1%
average across 5 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
EYP-1901
Phase 3 · Wet Age Related Macular Degeneration

Full Press Release Details

WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that George Elston, Chief Financial Officer of EyePoint Pharmaceuticals, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 2:30 p.m. ET.
A live webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary erodible Durasert E™ technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert® drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. For more information visit www.eyepointpharma.com.

Frequently Asked Questions

When will EyePoint Pharmaceuticals present at the Jefferies Healthcare Conference?

EyePoint Pharmaceuticals will present on June 7, 2023, at 2:30 p.m. ET.

Where can I access the presentation replay for EyePoint's event?

The presentation replay will be available in the Investors section of their website.

What technology does EyePoint Pharmaceuticals use for drug delivery?

EyePoint uses its proprietary Durasert E™ technology for sustained drug delivery.

What is EYP-1901 in EyePoint's pipeline?

EYP-1901 is an investigational anti-VEGF treatment in Phase 2 clinical trials.

Where is EyePoint Pharmaceuticals located?

EyePoint Pharmaceuticals is based in Watertown, Massachusetts.

ShareAdd on Google
Tags: EYPT Viatris Investor Conferences Healthcare EyePoint Pharmaceuticals healthcare conference Durasert technology eye disorders
Last updated: May 31, 2023

Biotech snapshot

Cash runway
$180M liquidity · $21M/mo burn
~8 mo
Medium dilution risk
Lead asset
EYP-1901Phase 3
Wet Age Related Macular Degeneration →

Catalyst track record

+28%
best trade around EYPT's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for EYPT.

See every catalyst's timing & PoA →